Product
Oxaliplatin+Capecitabine+Pembrolizumab
1 clinical trial
2 indications
Indication
Stomach CancerIndication
Esophageal CancerClinical trial
A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer.Status: Completed, Estimated PCD: 2023-02-06